Online inquiry

IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4172MR)

This product GTTS-WQ4172MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4172MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12299MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ1434MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ10309MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ14503MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ5810MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ6102MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ10002MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ8484MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hu1124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW